Oncology Peer Review On-The-Go: Emerging and Existing Treatment Regimens for Transplant-Ineligible DLBCL

News
Podcast

For the “Oncology Peer Review On-The-Go” podcast, CancerNetwork® sat down with Gilles Salles, MD, to discuss different treatment regimens for transplant-ineligible DLBCL in this special edition episode.

In this special episode of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork® spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL).

Salles discussed some of the available treatment options including tafasitamab (Monjuvi), chimeric antigen receptor T-cell therapies, selinexor (Xpovio), and antibody-drug conjugates. He also looked ahead at some of the upcoming research on the horizon, including the B-MIND trial (NCT02763319) investigating tafasitamab or rituximab (Rituxan) plus bendamustine.

Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Related Content
Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Elucidating the Clinical Landscape for Rare Lymphoma Treatment

Roman Fabbricatore
April 17th 2025
Article

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

CHMP Recommends Acalabrutinib Combo Approval in Untreated MCL

CHMP Recommends Acalabrutinib Combo Approval in Untreated MCL

Tim Cortese
March 31st 2025
Article

Results from the phase 3 ECHO trial showed PFS and OS improvements with acalabrutinib in the first-line treatment of MCL compared with standard of care.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

EC Approved Liso-cel in Pretreated Relapsed/Refractory Follicular Lymphoma

EC Approved Liso-cel in Pretreated Relapsed/Refractory Follicular Lymphoma

Tim Cortese
March 14th 2025
Article

Liso-cel has been approved by the European Commission for the treatment of adult patients with follicular lymphoma who received 2 or more prior lines of systemic therapy.

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Viviana Cortlana, MS4;Jade Gambill, BSc;Jenna Ghazal, BSc;Kennedy Itodo;Shreevikaa Kannan, PGY-5;Yan Leyfman, MD;Chandler H. Park, MD, FACP
March 7th 2025
Article

Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.